BioSpace News Archive

First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union

The market will accelerate at a CAGR of over 6% between 2019-2023

Latest patent complements Medicomp’s other patented technologies for clinical data filtering and the delivery of patient- and problem-specific data at the point of care

Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on a new analysis of a larger data set from Phase 3 studies.

Longtime correctional healthcare executive Teri Gregory has joined Corizon Health as vice president of operations for the state of Kansas, the company announced.

miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7th, at 4:30 p.m.

IntelGenx Corp., a leader in pharmaceutical films, announced that its 505 New Drug Application for RIZAPORT® VersaFilm® for the treatment of acute migraines has been accepted for review by the U.S. Food and Drug Administration

Compass Therapeutics, a biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced the appointment of a scientific advisory board made up of renowned immuno-oncology researchers with deep expertise in target biology, drug development and clinical trial design.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California.

GT Biopharma, Inc. announced that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity concerning a solid tumor targeting TriKE™ which demonstrates killing of non-small cell lung cancer tumor cells.